Quality & complianceOfficial

Teva metoclopramide tablets recalled in US over presence of foreign tablets or capsules

🇺🇸 FDA enforcement report · Wed 21 Oct 2026

FDA's enforcement report lists a Class II recall of Teva Pharmaceuticals USA's metoclopramide tablets, with nationwide US distribution and the recall still ongoing.

The US Food and Drug Administration has listed a Class II recall of Metoclopramide Tablets made by Teva Pharmaceuticals USA, Inc, in its enforcement report dated 21 October 2026. The recall number is D-0038-2027.

The stated reason is the presence of foreign tablets or capsules. The entry points to a mix-up risk in which other solid oral dosage forms may be found alongside the intended product.

The recall's status is ongoing, and the product was distributed nationwide in the United States.

As general context, the FDA assigns Class II to recalls where use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the chance of serious harm is considered remote.

The source text available to VigiEye contains no further detail, such as strengths, lot numbers, quantities, or the date the recall began. Those details would be found in the full enforcement report entry.

What it means for your team

  • US supply-chain and distribution teams should check the full FDA enforcement entry for D-0038-2027 for affected lots and strengths before acting on stock.
  • Quality teams may wish to review their own controls on mix-ups and foreign tablet or capsule contamination, especially in packaging and line clearance.
  • Pharmacovigilance teams could watch for reports from patients or pharmacists describing unexpected tablets or capsules in metoclopramide packs.
  • Market-access and supply planners should note the nationwide scope, as it may affect availability while the recall is ongoing.

Official source: FDA enforcement report ↗

Article written by VigiEye from the official source (FDA enforcement report). AI-assisted; check the source before acting.

More Quality & compliance All →